Uppsala, Sweden, 2014-01-21 13:08 CET (GLOBE NEWSWIRE) --
Oasmia’s Chief Financial Officer Weine Nejdemo has decided to retire. Weine, who turns 66 this year, will stay with the company until April 17.
The recruitment process for a replacement has been initiated.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
Mikael Widell, Vice President Communications, Oasmia Pharmaceutical AB. E-mail: firstname.lastname@example.org Phone: +46 (0) 18 50 54 40. www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia